Abstract Background: The prevalence of nonalcoholic steatohepatitis (NASH) is increasing every year, and there are very few approved therapeutic agents globally, making the search for potentially targeted therapeutic agents important
Weight loss is not a sprint
Research has explored retatrutide 24MG in metabolic science, including models and trials evaluating appetite signaling, glucose homeostasis, and energy expenditure pathways
What is unknown Whether any added pathway improves weight, body composition, function, safety, or long-term outcomes when paired with retatrutide
This dual action on diabetes control and weight management makes tirzepatide an attractive treatment option for individuals aiming to improve their overall health